Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4233 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Positive results for EntreMed drug in arthritis test

Preclinical studies demonstrated that daily oral administration of 2ME2 resulted in a dose-dependent decrease in inflammation and tissue destruction in two distinct animal models of rheumatoid arthritis. Treatment

Study supports Allon compounds

The two proprietary compounds are NAP, from which Allon has derived its first and second products AL-108 and AL-208, and ADNF-9, from which the company has derived product

Biocon and Nobex in cardiovascular research alliance

The collaboration combines the peptide production capabilities of Biocon with the proprietary oral peptide delivery technology of Nobex. The company’s plan to advance the oral human brain-type natriuretic

Mechanisms of rotenone action uncovered

Neuroscientists from the University at Buffalo have shown that rotenone, an environmental toxin linked specifically to Parkinson’s disease, damages dopamine producing neurons critical to body movement and muscle